Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review.

International forum of allergy & rhinology·2026
Same author

Sleep disturbances in patients with vasculitis.

Sleep medicine·2026
Same author

Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.

EULAR rheumatology open·2026
Same author

IgG4-related disease presenting as an omental mass.

BMJ case reports·2026
Same author

Correction: Comprehensive immune profiling identifies alterations in adaptive and innate immune responses in granulomatosis with polyangiitis patients in remission.

Frontiers in immunology·2026
Same author

Comprehensive immune profiling identifies alterations in adaptive and innate immune responses in granulomatosis with polyangiitis patients in remission.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 16, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Plasma exchange for systemic lupus erythematosus.

Christian Pagnoux1

  • 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université René Descartes, Paris, 27, rue du Faubourg Saint-Jacques, 75689 Paris Cedex 14, France. christian.pagnoux@cch.aphp.fr

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|March 21, 2007
PubMed
Summary

Plasma exchange shows limited efficacy for systemic lupus erythematosus but remains relevant for severe, refractory cases. It can be an adjuvant therapy for critical manifestations when combined with other treatments.

Related Experiment Videos

Last Updated: Jul 16, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Rheumatology
  • Nephrology
  • Hematology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
  • Extracorporeal therapies, including plasma exchange, are considered for severe SLE manifestations.
  • Initial studies on plasma exchange efficacy in SLE yielded inconclusive results.

Purpose of the Study:

  • To evaluate the role and efficacy of plasma exchange in managing systemic lupus erythematosus.
  • To identify specific patient subgroups and conditions where plasma exchange may be beneficial.
  • To explore future perspectives for extracorporeal therapies in SLE management.

Main Methods:

  • Review of non-controlled and retrospective studies on plasma exchange in SLE.
  • Analysis of plasma exchange as adjuvant therapy in combination with corticosteroids and immunosuppressants.
  • Consideration of newer technologies like immunoadsorption and biologics.

Main Results:

  • Plasma exchange efficacy in SLE is not broadly supported by initial retrospective data.
  • Plasma exchange remains a relevant option for selected patients with life-threatening or therapy-resistant SLE manifestations.
  • Effective use as adjuvant therapy for refractory lupus nephritis, alveolar hemorrhage, neuropsychiatric lupus, and other severe conditions.

Conclusions:

  • Plasma exchange can be a valuable adjuvant therapy for specific severe and refractory systemic lupus erythematosus manifestations.
  • Combination therapy with corticosteroids and immunosuppressants is crucial for refractory cases.
  • Emerging technologies like immunoadsorption may offer future advancements in SLE extracorporeal treatment.